Clinical Trials Logo

Painful Bladder Syndrome (PBS) clinical trials

View clinical trials related to Painful Bladder Syndrome (PBS).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06209008 Completed - Clinical trials for Interstitial Cystitis

Submucosal Intravesical Injection of Platelet-rich Plasma in the Treatment of Painful Bladder Syndrome

PRP
Start date: April 1, 2021
Phase: Phase 3
Study type: Interventional

Interstitial cystitis/painful bladder syndrome (IC/PBS) is characterized by a constellation of bladder symptoms, including urinary frequency, urgency, nocturia, and pelvic pain. Current intravesical IC/PBS treatment strategies include substances injected submucosally such as botulinum toxin A (BoNTA), or installed intravesically such as bacillus Calmette-Guerin (BCG), resiniferatoxin (RTX), lidocaine, chondroitin sulfate (CS), oxybutynin, and pentosan polysulfate (PPS). Plasma Rich Protein (PRP) is rich in growth factors, such as platelet-derived growth factor, epidermal growth factor, and transforming growth factor. With the help of these growth factors the defective epithelium can undergo proliferation, differentiation, and wound healing.